PF-04995274

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32N2O6
Molecular Weight	432.51
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC5(CN1CCC(COC2=NOC3=C2C(O[C@@H]4CCOC4)=CC=C3)CC1)CCOCC5

InChI

InChIKey=WLLOFQROROXOMO-GOSISDBHSA-N

InChI=1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2/t18-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H32N2O6
Molecular Weight	432.51
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23589342
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800031903

Pfizer was developing PF-4995274, an orally administered serotonin 4 receptor (5HT-4) agonist for the treatment of Alzheimer's disease. In 2011, the company discontinued the development of the compound.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 4 (5-HT4) receptor 39 Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23589342	Agonist 2678		0.92 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272 Sources: http://adisinsight.springer.com/drugs/800031903 https://clinicaltrials.gov/ct2/show/NCT01193062	Primary		Phase I 428	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Chem Scene	CS-0007316	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0007316
ChemShuttle	171827	https://www.chemshuttle.com/catalogsearch/result/?q=171827
Hangzhou APIChem Technology	AC-30621
MedChem Express	HY-18137	https://www.medchemexpress.com/search.html?q=HY-18137&ft=&fa=&fp=
MolPort	MolPort-046-697-135	https://www.molport.com/shop/molecule-link/MolPort-046-697-135
MolPort	MolPort-046-857-259	https://www.molport.com/shop/molecule-link/MolPort-046-857-259
Molnova	M11321	https://www.molnova.com/en/serch-list.html?keywords=M11321
MuseChem	I008671	https://www.musechem.com/product/I008671.html
eMolecules	222595681	https://orderbb.emolecules.com/search/#?query=222595681
mcule	MCULE-6461442130	https://mcule.com/MCULE-6461442130/

PubMed

Title	Date	PubMed
Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in human.	2013 Sep	23589342
Strategies toward optimization of the metabolism of a series of serotonin-4 partial agonists: investigation of azetidines as piperidine isosteres.	2016 Dec	26947511

Patents

Sample Use Guides

In Vivo Use Guide

oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg

Route of Administration: Oral

In Vitro Use Guide

In human functional cell lines, TBPT bound to 5-HT4b with EC50 value for receptor activation of 0.92 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:56:57 GMT 2023` Edited by `admin` on `Sat Dec 16 01:56:57 GMT 2023`
Record UNII	XI179PG9LV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PF-04995274

Common Name

English

(R)-4-((4-(((4-(TETRAHYDROFURAN-3-YLOXY)-1,2-BENZISOXAZOL-3-YL)OXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL

Systematic Name

English

Code System Code Type Description

PUBCHEM

53354764